About the job
Our Mission and Vision
At Unlearn, we are on a transformative journey to revolutionize clinical development, making every clinical trial smarter and more efficient. Leveraging the power of data, artificial intelligence, and digital twins, we enable rapid and robust studies that expedite the delivery of life-saving treatments to patients. Our commitment to this mission shapes every facet of our partnerships with biopharmaceutical companies, as we redefine how clinical trials are conceptualized, executed, and analyzed.
We are at the forefront of clinical development, instilling unmatched scientific credibility and replacing uncertainty with AI-driven precision. This clarity empowers stronger decision-making and enhances trial efficacy. Our goal is not just to disrupt the pharmaceutical sector; we aim to create meaningful and lasting change.
We firmly believe that AI will shape the future of medicine, and we are dedicated to building this future responsibly, rigorously, and in collaboration with our clinical development partners.
About Our Team
Our diverse team hails from various backgrounds, including machine learning, marketing, and more. Regardless of our origins, all Unlearners embody common traits:
- Ambition: We embrace big, challenging goals without hesitation.
- Disciplined Experimentation: We decompose our large objectives into manageable tasks, meeting frequently to monitor progress and adapt swiftly.
- Resilience: Setbacks motivate us to strive harder, as we never back down.
- Openness to Innovation: We resist complacency and thrive on new ideas.
- Effective Communication: Sharing knowledge is crucial, and we aim to make our interactions engaging.
- Team Orientation: We prioritize our mission first, the company second, the team third, and individual goals last.
Founded in 2017 and headquartered in San Francisco, Unlearn has garnered investment from leading venture firms like Altimeter, Insight Partners, Radical Ventures, 8VC, DCVC, and DCVC Bio, successfully closing our $50 million Series C funding round in January 2024.
If our mission and culture resonate with you, we encourage you to apply.

